J 2015

The miR-29 family in hematological malignancies

FIŠEROVÁ, Barbora, Lenka BEŠŠE, Lenka SEDLAŘÍKOVÁ, Roman HÁJEK, Sabina ŠEVČÍKOVÁ et. al.

Basic information

Original name

The miR-29 family in hematological malignancies

Authors

FIŠEROVÁ, Barbora (203 Czech Republic, belonging to the institution), Lenka BEŠŠE (203 Czech Republic, belonging to the institution), Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomedical Papers, Olomouc, Palacký University, 2015, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.924

RIV identification code

RIV/00216224:14110/15:00082058

Organization unit

Faculty of Medicine

DOI

UT WoS

000359128900003

Keywords in English

microRNA; miR-29 family; hematological malignancy; circulating miRNA

Tags

Tags

International impact, Reviewed
Změněno: 7/4/2016 15:37, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Background. MicroRNAs are short non-coding regulators of gene expression. The human miR-29 family consists of three members: miR-29a, miR-29b and miR-29c. Members of this family were found to be aberrantly expressed in various types of tumors, including hematological malignancies. This family was described to have both oncogenic and tumor suppressor features influencing various pathological processes, such as tumor growth and apoptosis. This review summarizes current knowledge about the miR-29 family in selected hematological malignancies. Conclusion. Recent research of miR-29 family in hematological malignancies has proven its oncogenic as well as tumor suppressive potential. Nevertheless, the level of current evidence is not sufficient, and data remain inconclusive.

Links

MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
MUNI/11/InGA17/2012, interní kód MU
Name: MikroRNA v patogenezi extramedulárního relapsu mnohočetného myelomu
Investor: Masaryk University